Institute of Human Genetics, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany.
Department of Ophthalmology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.
Sci Rep. 2024 Oct 26;14(1):25529. doi: 10.1038/s41598-024-77014-4.
Inherited retinal dystrophies (IRDs) and inherited optic neuropathies (IONs) are characterized by distinct genetic causes and molecular mechanisms that can lead to varying degrees of visual impairment. The discovery of pathogenic variants in numerous genes associated with these conditions has deepened our understanding of the molecular pathways that influence both vision and disease manifestation and may ultimately lead to novel therapeutic approaches. Over the past 18 years, our DNA diagnostics unit has been performing genetic testing on patients suspected of having IRD or ION, using state-of-the-art mutation detection technologies that are continuously updated. This report presents a retrospective analysis of genetic data from 6237 IRD and 780 ION patients. Out of these, 3054 IRD patients (49.0%) and 211 ION patients (27.1%) received a definitive molecular diagnosis, with disease-causing variants identified in 139 different genes. The genes most implicated in disease pathologies are ABCA4, accounting for 23.8% of all IRD/ION index cases, followed by BEST1 (7.8%), USH2A (6.2%), PRPH2 (5.7%), RPGR (5.6%), RS1 (5.5%), OPA1 (4.3%), and RHO (3.1%). Our study has compiled the most extensive dataset in combined IRD/ION diagnostics to date and offers valuable insights into the frequencies of mutant alleles and the efficiency of mutation detection in various inherited retinal conditions.
遗传性视网膜病变(IRDs)和遗传性视神经病变(IONs)的特征是具有不同的遗传原因和分子机制,这些原因和机制可导致不同程度的视力损害。在与这些病症相关的众多基因中发现致病变异,加深了我们对影响视力和疾病表现的分子途径的理解,并可能最终导致新的治疗方法。在过去的 18 年中,我们的 DNA 诊断部门一直在对疑似患有 IRD 或 ION 的患者进行基因检测,使用的是不断更新的最先进的突变检测技术。本报告对 6237 例 IRD 和 780 例 ION 患者的遗传数据进行了回顾性分析。在这些患者中,3054 例 IRD 患者(49.0%)和 211 例 ION 患者(27.1%)获得了明确的分子诊断,在 139 个不同的基因中发现了致病变异。在疾病病理中最受牵连的基因是 ABCA4,占所有 IRD/ION 索引病例的 23.8%,其次是 BEST1(7.8%)、USH2A(6.2%)、PRPH2(5.7%)、RPGR(5.6%)、RS1(5.5%)、OPA1(4.3%)和 RHO(3.1%)。我们的研究汇集了迄今为止在联合 IRD/ION 诊断中最广泛的数据集,为各种遗传性视网膜疾病中突变等位基因的频率和突变检测效率提供了有价值的见解。